| Step | Purpose | Key actions/tests | Evidence/pitfalls | Notes on real-world implementation |
|---|---|---|---|---|
| 1. Recognize a compatible syndrome | Identify patients who warrant urgent PNS workup | Assess for subacute/rapidly progressive neurologic syndromes; classify presentation as high-risk phenotype or possible intermediate-risk phenotype under 2021 PNS-Care framework; exclude direct cancer effects, infection, toxic-metabolic causes, treatment toxicity, stroke, and degenerative disease (pqac-00000002, pqac-00000025, pqac-00000007, pqac-00000001) | PNS diagnosis is syndromic first, not antibody-first; no neurologic syndrome is exclusively paraneoplastic, so overcalling based on isolated antibody findings is a major pitfall (pqac-00000002, pqac-00000020) | In practice, neurology-oncology review early in the course improves triage and helps decide whether to pursue full PNS-Care scoring and malignancy search immediately |
| 2. Apply PNS-Care risk logic early | Estimate likelihood of true paraneoplastic disease and prioritize workup urgency | Combine phenotype risk, antibody risk category, presence/absence of cancer, and follow-up context using PNS-Care approach; note that definite PNS usually requires high- or intermediate-risk antibodies except opsoclonus-myoclonus (pqac-00000002, pqac-00000016) | 2021 criteria replace “classical/non-classical” language with high-/intermediate-risk phenotypes and antibodies; probable and definite cases should both be managed urgently (pqac-00000002, pqac-00000012) | Helpful for standardization, but some real-world patients with likely PNS may still fall below probable/definite thresholds, so clinical judgment remains essential |
| 3. Obtain paired serum and CSF | Maximize diagnostic sensitivity and reduce false interpretation | Send both serum and CSF for neuronal antibody testing plus routine CSF studies: cell count, protein, oligoclonal bands/IgG index; pair antibody testing with inflammatory markers and syndrome-specific studies (pqac-00000003, pqac-00000005, pqac-00000026, pqac-00000001) | Serum-only testing can mislead; false positives are suggested by atypical presentations, very low titers, or antibodies found only in serum and not CSF; LGI1 is an exception where serum may be more sensitive (pqac-00000003, pqac-00000021) | A practical default is “serum + CSF together” at first lumbar puncture to avoid repeat procedures and delayed interpretation |
| 4. Use confirmatory antibody methods, not single commercial assays alone | Improve positive predictive value (PPV) and clinical specificity | Prefer multistep testing with tissue-based confirmation (IHC/IIF) and/or orthogonal assays instead of relying on isolated immunoblot or CBA results (pqac-00000022, pqac-00000021) | In the Netherlands nationwide study, specificity was usually high, but PPV was only modest for several rare-disease tests; serum CBA-only PPVs were 69.7% for NMDAR, 71.7% for CASPR2, 78.8% for GABABR, and 91.8% for LGI1, improving to 97.1%, 94.3%, 100%, and 96.4% with IHC confirmation; anti-Yo PPV improved from 28.8% with immunoblot alone to 77.8% with immunoblot+IIF (pqac-00000021, pqac-00000022) | Commercial “line blot positive” results should not be acted on in isolation, especially for intracellular/onconeural antibodies in low-pretest-probability settings |
| 5. Interpret antibodies by antigen class and cancer-risk category | Link serology to mechanism, prognosis, and tumor search strategy | Distinguish intracellular/high-risk antibodies from neuronal-surface antibodies; use high-risk antibodies to direct urgent tumor search and counseling; interpret lower-risk antibodies in syndrome context (pqac-00000002, pqac-00000025, pqac-00000007, pqac-00000001) | High-risk antibodies have >70% cancer association; intermediate-risk 30%–70%; lower-risk <30%; intracellular antibodies are often markers of T-cell-mediated disease rather than directly pathogenic, whereas surface antibodies are more often directly pathogenic and treatment responsive (pqac-00000002, pqac-00000025, pqac-00000007) | Reporting should include antigen, sample type, method, titer when available, and risk category—not just “positive/negative” |
| 6. Perform core neurologic phenotyping studies | Support syndrome definition and identify inflammatory evidence | Obtain MRI brain/spine as indicated, EEG for encephalitic/seizure presentations, EMG/NCS for neuropathy/LEMS, and syndrome-specific testing (pqac-00000005, pqac-00000004) | CSF pleocytosis, CSF-exclusive oligoclonal bands, and MRI inflammatory changes support autoimmune/paraneoplastic etiologies but are not specific (pqac-00000026, pqac-00000003) | These studies often provide the “objective inflammation” needed to justify ongoing tumor search even before antibodies return |
| 7. Search for occult malignancy at baseline | Detect the causative tumor and satisfy diagnostic criteria | Use whole-body CT and/or FDG-PET/CT; add targeted tests guided by phenotype/antibody, such as testicular ultrasound for anti-Ma2/KLHL11 or pelvic imaging for teratoma-associated syndromes (pqac-00000003, pqac-00000005, pqac-00000026, pqac-00000004) | About 80% of patients have positive tumor screening at first assessment in one recent review summary; CT, ultrasound, MRI, and FDG-PET are complementary rather than mutually exclusive (pqac-00000003) | Baseline tumor search should be parallel with neurologic workup, not delayed until antibodies finalize |
| 8. Repeat tumor screening when initial studies are negative | Capture cancers that are initially occult | If first malignancy screen is negative, repeat every 3–6 months initially, then every 6 months for up to 4 years, especially in patients with high-risk phenotypes/antibodies (pqac-00000003, pqac-00000004) | A common pitfall is stopping after one negative CT; many PNS precede tumor diagnosis, and delayed cancer detection is well recognized (pqac-00000003, pqac-00000004) | Build repeat imaging into the care plan at discharge so follow-up does not depend on ad hoc reassessment |
| 9. Reassess discordant or low-probability cases | Prevent misdiagnosis and unnecessary immunotherapy | Revisit alternative diagnoses when syndrome is low-risk, no tumor is found, antibody is low-titer/serum-only, or phenotype-antibody pairing is atypical (pqac-00000003, pqac-00000020, pqac-00000022) | Mass testing in rare diseases lowers PPV; clinically irrelevant positives occur, particularly when ordering broad panels in nonspecific neurologic presentations (pqac-00000022, pqac-00000021) | Multidisciplinary case conference is useful for “positive antibody, wrong phenotype” cases |
| 10. Document diagnostic confidence and act on urgency | Translate workup into management pathway | Record phenotype, antibody class/risk, cancer status, inflammatory evidence, and final certainty level (possible/probable/definite); begin treatment/tumor-directed management without waiting for perfect certainty when suspicion is strong (pqac-00000002, pqac-00000003, pqac-00000012) | The 2021 framework was designed for care and research standardization, but delayed treatment worsens outcomes; probable PNS should not be considered low priority (pqac-00000002, pqac-00000012) | A practical final note in reports is whether the patient meets or approaches PNS-Care probable/definite thresholds and what further testing would change classification |


*Table: This table summarizes a practical stepwise diagnostic workflow for suspected paraneoplastic neurological syndromes, integrating the 2021 PNS-Care framework with real-world assay pitfalls and tumor-screening recommendations. It is useful as a concise clinical checklist for applying recent evidence to workup and implementation.*